Crescent Biopharma, Inc.: updates and filings

CBIONASDAQHealthcare · Pharmaceutical Preparations

Price

$13.00

November 20, 2026Market cap $506M

What Ploutos Investor adds for Crescent Biopharma

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 10 fiscal years, from 2012
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 68 daysAround Jan 29, 2027 · for Q4 2026

last Nov 12, 2026next Jan 29, 2027

An estimate from when it has reported before, and the timing has varied a little. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Feb 26, 2026 latest annualNov 12, 2026 latest quarterly
  • Nov 16, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 16, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 16, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 16, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 12, 2026Results of operations
    Form8-K
  • Nov 12, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Oct 27, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Oct 15, 2026Other material events
    Form8-K
  • Sep 18, 2026Shares registered for employees
    FormS-8
  • Aug 14, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Jul 31, 2026Filing
    FormEFFECT
  • Jul 30, 2026Filing
    FormPOS AM
  • Jul 30, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Jul 30, 2026Results of operations
    Form8-K
  • Jul 20, 2026Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Jul 15, 2026Other material events
    Form8-K
  • Jul 14, 2026Results of operations
    Form8-K
  • Jul 10, 2026Filing
    FormEFFECT
  • Jul 1, 2026Shelf registration for future offerings
    FormS-3
  • Jun 22, 2026Quarterly report (amendment)for the period to Mar 31, 2026
    Form10-Q/A
  • Jun 3, 2026Shareholder vote
    Form8-K
  • May 15, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • May 15, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Apr 29, 2026Results of operations
    Form8-K
  • Apr 29, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jul 10, 2003.

The full analysis

What do Crescent Biopharma's filings show?

The filings are where every one of Crescent Biopharma's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.